mocyte globulin (ATG). However, refractory GVHD and an increase in infection rate still represent major problems. Among alternative treatments, PUVA photochemotherapy A 45-year-old female patient with CML underwent allogeneic BMT and developed two episodes of acute (PUVA = 8-methoxypsoralen (MOP) in conjunction with UVA light) has been used successfully in selected cases of GVHD. The first episode of acute cutaneous GVHD grade II (day +17) responded well to systemic CsA and chronic GVHD. Based on its beneficial effect, ie the decrease of organ a lasting complete remission was achieved. To our knowledge this is the first report of successful treatment rejection rate in transplant recipients, and because GVHD shows features of autoimmune disease, mediated by autoof early-onset, lichen-planus-like GVHD after allogeneic BMT with ECP.
Based on its beneficial effect, ie the decrease of organ a lasting complete remission was achieved. To our knowledge this is the first report of successful treatment rejection rate in transplant recipients, and because GVHD shows features of autoimmune disease, mediated by autoof early-onset, lichen-planus-like GVHD after allogeneic BMT with ECP.
reactive T cells and cytokines, ECP has been attempted to treat otherwise refractory GVHD.
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Case report
GVHD occurs in up to 50% of patients undergoing matched We report a 45-year-old female Caucasian patient with Ph+ related allogeneic bone marrow transplantation. 1 GVHD CML in acceleration which was first diagnosed in 1993. affects mostly the skin, the liver and the gastrointestinal After conditioning with fractionated total body irradiation tract. In most cases the cutaneous symptoms of acute (12 Gy) and cyclophosphamide (120 mg/kg body weight) GVHD develop before day +100 following BMT and the patient received the bone marrow (BM) from her HLApresent as a localized or generalized pruritic macular-papuidentical brother in December 1994. On day +17 she lar rash, which may progress to erythroderma or even a developed acute cutaneous GVHD grade II and liver toxic epidermal necrolysis (TEN)-like eruption. Chronic GVHD grade I which was treated with increasing doses of cutaneous GVHD usually occurs after day +100, with an CsA and prednisolone (1 mg/kg body weight per day). One early, lichen-planus-like or late, sclerodermatous phase, the month later she developed erythroderma (grade III, GVHD) latter often being the result of a preceding lichen-planuswhich did not improve significantly with increased doses like eruption.
of systemic steroids (2 mg/kg body weight per day) with The pathogenic events are related to the interaction of maintenance on CsA. During the following month the immunocompetent T cells of the donor with major and/or patient showed signs of lichen-planus-like GVHD (Figures minor histocompatibility antigens (MHC, miHA) expressed 1a and 2) with involvement of the oral mucosa. Histology by cells or tissues of an immunosuppressed host. lichen-planus-like GVHD. Intermittent episodes of oral cutaneous GVHD. During the entire course of the ECP treatment no side-effects (nausea, vomiting, dizziness) or candidiasis and CMV reactivation were treated according to established treatment regimens. Absence of response to infections occurred. The patient has been off ECP for over 8 months, has no increased doses of steroids led to the initiation of ECP on day +89.
signs of cutaneous disease and has an excellent performance status. At present she is receiving no immunosuppres-ECP was performed using the UVAR photopheresis system (Therakos, West Chester, PA, USA). Briefly, 240 ml sive therapy. of buffy coat and 300 ml plasma were removed during each treatment by a standard apheresis procedure and diluted with 200 ml of saline solution. 0.2 mg of 8-methoxypsorDiscussion alen (Gerot, Austria) were added to the final enriched lymphocyte solution containing 6 × 10 9 cells. The solution was ECP is an established treatment for cutaneous T cell lymphoma, 10 and has also been used successfully in patients exposed for 90 min to a UVA light source (2 J/cm 2 /cell) in an extracorporeal system, and then returned to the with autoimmune disorders (eg pemphigus vulgaris, progressive systemic sclerosis, systemic lupus erythematosus). patient. 9 The mean treatment time for the photopheresis procedure was 3-4 h. Each treatment cycle consisted of two Recent reports indicated that ECP may be used successfully in selected, refractory cases of late-phase chronic sclerodertreatments performed on 2 consecutive days.
Our patient was treated every 2 weeks for 3 months, and matous GVHD. 7,8 Based on our observed clinical response to ECP treatment of patients with sclerodermatous chronic thereafter monthly for 3 months. Concomitant therapy included daily CsA and oral prednisolone 1 mg/kg on an GVHD, the very low side-effect profile and its positive effect on other T cell-mediated diseases, we decided to treat alternate day basis. After four cycles of ECP a significant improvement of erythroderma and clearance of the lichena patient with early onset lichen-planus-like GVHD with ECP. The BM recipient had had recurrent episodes of acute oid papules was observed. Prednisolone was stopped after four cycles of ECP, and CsA was tapered from 12 mg/kg cutaneous GVHD, grade II-III between day +17 and day +60 after BMT which had not responded to conventional to 4 mg/kg daily until the end of ECP therapy. Six months after initiation of ECP no clinical signs of lichen-planusimmunosuppressive therapy. As her cutaneous lesions progressed into a lichen-planus-like eruption, ECP was like GVHD were noted (Figure 1b) . At this time a control biopsy was taken which showed the histological picture of initiated. In former years lichen-planus-like eruptions have been regarded as a symptom of early-onset chronic GVHD. normal skin, thus confirming complete resolution of number of patients are needed to prove the efficacy of ECP in this setting.
In our opinion successful treatment with ECP appears to depend on early initiation of this therapy, ie as soon as clinical and histological signs of lichen-planus-like GVHD occur, and no response to conventional immunosuppressive therapy is noted. Moreover, we postulate that complete and long-standing remission including the prevention of latephase, chronic sclerodermatous GVHD can be achieved by ECP.
